
strand 🗰

Strand's qPCR Reporting Software (PQRS)

Our in-house customizable infectious-disease reporting end-to-end solution processes qPCR input and generates a comprehensive and actionable report with detailed pathogen profiles, antibiotic susceptibility status, and drug recommendations.


- 2-Minute Report Turnaround Time
- Highly Customizable Features
- Seamless LIMS Integration
- Broad test range (expandable)
 - 91 Pathogens
 - 42 AMR Genes
 - 513 Pathogen-Drug recommendations



The PQRS Workflow

- PQRS software offers an end-to-end solution for qPCR reporting.
- The process is initiated by inputting qPCR result files, and the PQRS platform can be customized to handle other input data types as well.
- Additionally, culture test output files can also be entered into the workflow, thus enabling combined reporting of pathogens, AMR genes and antibiotic susceptibility testing (AST).
- A manual QC step is performed to ensure accuracy.

- Following this, a comprehensive report based on a configurable template is compiled and generated.
- A brief review by a senior scientist follows and the report is made available to the end user as a PDF download.
- The entire workflow from file input through QC to report generation – is completed in under 2 minutes.
- PQRS can be integrated into existing LIMS setups, enabling seamless report generation and retrieval.



Tailored qPCR and AST Report with Medication Options

Our customizable report offers the following benefits

- 1. Clinician-approved format: We incorporate client-specific requirements into the qPCR report through frequent interactions with the clinician team.
- 2. Combined qPCR and AST reporting: The end report captures the qPCRidentified pathogens, antibiotic resistance genes, as well as antibiotic susceptibility test results, offering insights on infectious pathogens as well as AST status.
- Broad array of medication options: Our platform currently supports over 500 drug-pathogen recommendations across 91 pathogens and 42 resistance genes. Clinicians can choose from multiple antibiotic recommendations based on pathogen profiles to make patient-tailored decisions.

- 4. Dosage guidance: PQRS can be configured to include medication dosage guidance based on pathogen profiles and antibiotic susceptibility.
- Additional customization: Reports can be customized to include drug tiers, and administration routes based on curated treatment protocols and clinician preferences.

Reports can also have **embedded audit logs** to track report creation times and approval status, and optionally include **sign-offs by subject matter experts**.

Minimal and basic customizations, such as branding, logo, and template modifications, can be completed in **~2 weeks**. Additional features, depending on their complexity, can be implemented in 1–3 months.


The high-level summary in the first page is followed by a detailed account of identified pathogen profiles.

	Patient	5	Fract Infe	haryngaal Swab	eport Provider Information	Culture and Antibiotic Susceptibility Profiling
Pathogen an	DO8 Sex	Final Test Re entification and Antibio Comments Approved	extrated Date : 6/1/20 eport Date : 01/25/ port ptic Resistance Prol	23 2024		Pathogen Identification by culture method Rebelling prevention the Heavy growth
Positive By PCR Policy CR Policy antibiotic presentation (C: 14.924 Policy antibiotic presentation) Policy antibiotic presistance genes were detected:						Centered Organisms 4 Control C
PCR Ct Ranges	Ct < 20	Ct 20 - 23	0:23-25	Ct 25 - 28	Ct 28-30	
Estimated CFU/mL	>1x10 [#]	1x10 ²	1x10 ⁸	1x10 ⁵	<1x10*	Sensitive (S): indicates the organism(s) is susceptible to the antibiotic.
Suggested Interpretation	Very high pathagan absentance Host Hely cauation infections again, including in a patymorphial infection.	High pathogen abunfance (Any significant casistive infaction agent.	Moderato pathogen alkondanse Pomertally canastrive inflectiour agent ar unspectally from indepling catheter	Low pathogen alreadence Uhtikely causelike infectious agent, hus in ontain denial instrug- may be regarable as potentially coustine, plaze complete with polern's symptome and medical history.	Veryive or no significant perhogen abundance Alaci liely orogoniut focu or conservative in orbital clinical settings, cassifie onsected a possible enrecying pathogen for incoment infection.	Intermediate (II) indicates the organism(1) is insceptible to the antibiotic but not at a level required to ensure effectiveness. Resident of UII indicates the organism(1) in and susceptible. Grey Sec. Agent not assigned against participation Reference method and interpretive criteria based on the Clinical and Laboratory Standards Institute (CLS) M100 document, 12nd editors.
An and a second	A Bugata KS much des part A Bugata KS much des on the Musica KS much way on Jakapa subs is the central of the patient hoices	constraint with the absence of contraints with collarse results of contraints with the contraint of the second second second second roflox.acin, Fosformyci atbility results. The detection	a potential publicipe, a in imply clinically signific in , Gentamicin, Li of antibistic resistance p	evofloxacin, Nitro	titled by callues that are not ent. Previden sideal discretion fur antion,	

Reference Databases and Compliances

- The PQRS platform is equipped with an infectious-disease knowledge base curated by referencing established and licensed publicly available data sources.
- The knowledge base currently caters to UTI panels, but is evolving to include other panels, such as the respiratory pathogens panels (RPP), women's health, and wound

healing panels. Thus, it can be adapted and augmented to align with the clients panels and evolving treatment protocols to ensure accurate and relevant medical suggestions. • Our privacy and security protocols also ensure that patient data remains confidential as per HIPAA guidelines, and the data received through our API is HL7 compliant.



Recent Stories

We worked with a US-based CLIA/CAP-certified diagnostic laboratory offering infectious-disease testing to deliver a bespoke PQRS solution:

- 1. We customized the report to include all medication choices without details on tiers, route of administration, or dosage.
- 2. The antibiotic choices provided in the report were filtered for those approved in the US and referred to by their US trade names instead of generic names.
- 3. The report generation process was modified to require a medical director's approval.
- 4. The report was made available in both PDF and JSON formats.

Strand Life Sciences works with marquee genetics diagnostics, sequencing instrument, pharma and biotech companies to accelerate bioinformatics and software development See our website for recent Case Studies and to get in touch!



Presence in **20+** Countries



♀ 7th Floor, MSR North Tower, #144, Outer Ring Road, Nagavara, Bengaluru - 560045

+919980448044

₩ hello@strandls.com

⊕ strandls.com